Literature DB >> 7822778

CD28 costimulation up-regulates long-term IL-2R beta expression in human T cells through combined transcriptional and post-transcriptional regulation.

C Cerdan1, Y Martin, M Courcoul, C Mawas, F Birg, D Olive.   

Abstract

Costimulatory molecules such as CD28 are required for induction of T cell clonal expansion and for prevention of T cell unresponsiveness. In combination with either CD3 or CD2 triggering, CD28 was shown to enhance T cell proliferation, cytolytic activity, production of cytokines and especially of IL-2, and expression of the IL-2R alpha-chain (IL-2R alpha). We and others have demonstrated that the costimulatory effect of CD28 on both IL-2 and IL-2R alpha expression results from a coordinated transcriptional activation of their genes and transcript stabilization. We show here that the CD28 stimulation, together with CD2, leads to a prolonged up-regulation of the constitutive expression of the IL-2R beta-chain in human peripheral T cells. As for IL-2R alpha, the increase in IL-2R beta gene expression seems to result from both transcriptional activation and transcript stabilization. In addition, IL-2 differentially regulates its own receptors, as only expression of IL-2R alpha, but not of IL-2R beta, is largely inhibited, at both the mRNA and protein levels, by blocking IL-2R mAbs. We propose that the long lasting T cell proliferation mediated by the CD2 and CD28 costimulation is mainly the consequence of the high and prolonged expression of both the IL-2R alpha- and beta-chains.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822778

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes.

Authors:  Arvind Raghavan; Rachel L Ogilvie; Cavan Reilly; Michelle L Abelson; Shalini Raghavan; Jayprakash Vasdewani; Mitchell Krathwohl; Paul R Bohjanen
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

2.  The immediate-early gene product Egr-1 regulates the human interleukin-2 receptor beta-chain promoter through noncanonical Egr and Sp1 binding sites.

Authors:  J X Lin; W J Leonard
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

3.  A binding factor for interleukin 2 mRNA.

Authors:  J Hua; V Paetkau
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

Review 4.  Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Authors:  Prakash Manikwar; Paul Kiptoo; Ahmed H Badawi; Barlas Büyüktimkin; Teruna J Siahaan
Journal:  Med Res Rev       Date:  2011-03-23       Impact factor: 12.944

5.  Reduced expression of the interleukin-2-receptor gamma chain on cord blood lymphocytes: relationship to functional immaturity of the neonatal immune response.

Authors:  H Zola; M Fusco; H Weedon; P J Macardle; J Ridings; D M Roberton
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

Review 6.  CD28: a signalling perspective.

Authors:  S G Ward
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

7.  Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28.

Authors:  R V Parry; D Olive; J Westwick; D M Sansom; S G Ward
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

8.  Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens.

Authors:  E Muraille; S Devos; K Thielemans; J Urbain; M Moser; O Leo
Journal:  Immunology       Date:  1996-10       Impact factor: 7.397

9.  Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale.

Authors:  H Bohnenkamp; U Hilbert; T Noll
Journal:  Cytotechnology       Date:  2002-01       Impact factor: 2.058

10.  Molecular mechanisms involved in the aging of the T-cell immune response.

Authors:  Marco Antonio Moro-García; Rebeca Alonso-Arias; Carlos López-Larrea
Journal:  Curr Genomics       Date:  2012-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.